Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEPs Approve EMA Move To Amsterdam, But Insist Deadlines Must Be Met

Executive Summary

An EU parliamentary committee has OKd the EMA’s move to Amsterdam, but with caveats. MEPs are unhappy with the way the agency’s new home was decided and have called for changes to the procedure used to choose EU agency locations in future.

You may also be interested in...



Brexit Won’t Delay Drug Approvals, EMA’s Rasi Reassures Industry

The EU’s centralized drug approval process will not be disrupted regardless of the number of employees the European Medicines Agency might lose when it relocates from London to Amsterdam, Guido Rasi pledged yesterday at the DIA Europe 2018 conference.

EMA Queries Cost Of New Dutch HQ As Milan Steps Up Legal Fight

The Dutch government has insisted that the relocation of the European Medicines Agency to Amsterdam will go smoothly and that the agency’s permanent headquarters will be ready on time, despite an argument over the costs of the new premises and a renewed drive by Italy to have the EMA located in Milan.

UK Spending £2.9bn On Seven COVID-19 Vaccines

The UK government says it is on track to vaccinate the 15 million most vulnerable people by mid-February, and that a “major study” is under way to assess the potential impact of the new UK variant on vaccine efficacy.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel